GENESIS MICROCHIP INC
10-Q, 2000-11-14
SEMICONDUCTORS & RELATED DEVICES
Previous: AMERICAN RESIDENTIAL EAGLE BOND TRUST 1999-2 COLLATERALIZED, 15-15D, 2000-11-14
Next: GENESIS MICROCHIP INC, 10-Q, EX-10.1, 2000-11-14



<PAGE>

                      SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC 20549

                               -----------------

                                   FORM 10-Q

                                  (mark one)

             [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                    OF THE SECURITIES EXCHANGE ACT OF 1934

               FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000

                                      OR

             [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                    OF THE SECURITIES EXCHANGE ACT OF 1934

  FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________

                            COMMISSION FILE NUMBER:
                                   000-29592

                        GENESIS MICROCHIP INCORPORATED
            (Exact name of registrant as specified in its charter)

            NOVA SCOTIA, CANADA                         N/A
      (State or other jurisdiction of             (I.R.S. Employer
       incorporation or organization)             Identification No.)

        165 COMMERCE VALLEY DRIVE WEST
        THORNHILL, ONTARIO, CANADA                                  L3T 7V8
        (Address of principal executive offices)                    (Zip Code)

      REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (905) 889-5400

            Former name, former address and former fiscal year if
                          changed since last report.

                              Former address: N/A

                            Former Fiscal Year: N/A

            Indicate by check mark whether the registrant (1) has filed all
        reports required to be filed by Section 13 or 15 (d) of the Securities
        Exchange Act of 1934 during the preceding 12 months (or for such shorter
        period that the registrant was required to file such reports), and (2)
        has been subject to such filing requirements for the past 90 days.

                                Yes [X] No [_]

        There were 19,359,849 shares of the registrant's common shares issued
        and outstanding as of September 30, 2000.
<PAGE>

                        GENESIS MICROCHIP INCORPORATED
                                   FORM 10-Q
                     THREE MONTHS ENDED SEPTEMBER 30, 2000

                                     Index

<TABLE>
<CAPTION>
Item Number                                                                                       Page
-----------                                                                                       ----
<S>                                                                                               <C>
Part I:  Financial Information
      Item 1.  Financial Statements
           Condensed Consolidated Balance Sheets at March 31, 2000 and September 30, 2000            1
           Condensed Consolidated Statements of Operations for the three and six month
              periods ended September 30, 2000 and September 30, 1999                                2
           Condensed Consolidated Statements of Cash Flows for the six month periods ended
              September 30, 2000 and September 30, 1999                                              3
           Notes To Condensed Consolidated Financial Statements                                      4

      Item 2.  Management's Discussion and Analysis of Financial Condition and Results of
                 Operations                                                                          6

      Item 3.  Quantitative and Qualitative Disclosures About Market Risk                           14

Part II: Other Information
      Item 1.  Legal Proceedings                                                                    14
      Item 2.  Changes in Securities                                                                 *
      Item 3.  Defaults Upon Senior Securities                                                       *
      Item 4.  Submission of Matters to a Vote of Security Holders                                  14
      Item 5.  Other Information                                                                     *
      Item 6.  Exhibits and Reports on Form 8-K                                                     15

Signature                                                                                           15
</TABLE>

 * No information has been provided because this item is not applicable.

                                      -i-
<PAGE>

PART I:  FINANCIAL INFORMATION

ITEM 1:  FINANCIAL STATEMENTS


                        GENESIS MICROCHIP INCORPORATED
                     CONDENSED CONSOLIDATED BALANCE SHEETS
                 (dollar amounts in thousands of U.S. dollars)

<TABLE>
<CAPTION>
                                               ASSETS

                                                                            September 30,  March 31,
                                                                                2000          2000
                                                                             (unaudited)
                                                                           ---------------------------
<S>                                                                        <C>              <C>
Current assets:
    Cash and cash equivalents                                                    $ 33,396   $ 42,942

    Accounts receivable trade, net of allowance for doubtful accounts
     of $230 at September 30, 2000 and March 31, 2000                              11,493      6,023
    Income taxes recoverable                                                        1,235      1,111
    Inventory                                                                       7,126      4,714
    Investment held for resale                                                      1,100      1,100
    Other                                                                           2,291        797
                                                                          ---------------------------
       Total current assets                                                        56,641     56,687
Capital assets                                                                     11,488     12,000
Deferred income taxes                                                               3,231      3,024
Investment, at cost                                                                 2,021         80
                                                                          ---------------------------
          Total assets                                                           $ 73,381   $ 71,791
                                                                          ===========================

                                LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
    Accounts payable                                                             $  1,057   $  1,963
    Accrued liabilities                                                             1,582      3,967
    Current portion of loans payable                                                   94         96
                                                                          ---------------------------
       Total current liabilities                                                    2,733      6,026
Long-term liabilities:
    Loans payable                                                                     418        518
                                                                          ---------------------------
       Total liabilities                                                            3,151      6,544
Shareholders' equity:
   Special shares:
   Authorized - 1,000,000,000 shares without par value Issued and
   outstanding - no shares at September 30 or March 31 Common shares:
   Authorized - 1,000,000,000 shares without par value Issued and
   outstanding - 19,359,849 shares at September 30 and
   19,140,482 shares at March 31                                                   73,628     72,225
    Additional paid in capital                                                      1,293      1,293
    Cumulative other comprehensive loss                                               (94)       (94)
    Deferred compensation                                                            (223)      (273)
    Deficit                                                                        (4,374)    (7,904)
                                                                          ---------------------------
       Total shareholders' equity                                                  70,230     65,247
                                                                          ---------------------------
          Total liabilities and shareholders' equity                             $ 73,381   $ 71,791
                                                                          ===========================
</TABLE>

See accompanying notes to condensed consolidated financial statements.

                                      -1-
<PAGE>

                        GENESIS MICROCHIP INCORPORATED
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (dollar amounts in thousands of U.S. dollars, except per share amounts)
                                  (unaudited)

<TABLE>
<CAPTION>
                                                    Three Months Ended           Six Months Ended
                                                  September     September     September    September
                                                  30, 2000      30, 1999      30, 2000      30, 1999
                                                -------------------------------------------------------
<S>                                             <C>             <C>           <C>          <C>
Revenues                                              $15,040       $16,362       $27,852      $32,668
Cost of revenues                                        5,603         5,002         9,957       10,266
                                                -------------------------------------------------------
Gross profit                                            9,437        11,360        17,895       22,402

Operating expenses:
   Research and development                             4,417         3,986         8,465        7,566
   Selling, general and administrative                  3,553         3,112         6,742        6,385
   Merger-related costs                                     -             -             -        3,455
                                                -------------------------------------------------------
      Total operating expenses                          7,970         7,098        15,207       17,406
                                                -------------------------------------------------------
Income from operations                                  1,467         4,262         2,688        4,996
Interest income                                           739           515         1,253          932
                                                -------------------------------------------------------
Income before income taxes                              2,206         4,777         3,941        5,928
Provision for income taxes                                241           751           411          629
                                                -------------------------------------------------------
Net income                                            $ 1,965       $ 4,026       $ 3,530      $ 5,299
                                                =======================================================

Earnings per share:
       Basic                                          $  0.10       $  0.22       $  0.18      $  0.29
       Diluted                                        $  0.10       $  0.20       $  0.18      $  0.27

Weighted average number of common
shares outstanding (in thousands):
       Basic                                           19,298        18,499        19,241       18,437
       Diluted                                         19,963        19,784        19,902       19,808
</TABLE>

See accompanying notes to condensed consolidated financial statements.

                                      -2-
<PAGE>

                        GENESIS MICROCHIP INCORPORATED
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                 (dollar amounts in thousands of U.S. dollars)
                                  (unaudited)

<TABLE>
<CAPTION>
                                                                                Six Months Ended
                                                                             September     September
                                                                             30, 2000      30, 1999
                                                                           ----------------------------
<S>                                                                        <C>             <C>
Cash flows from operating activities:
       Net income                                                                $ 3,530       $ 5,299
       Adjustments to reconcile net income to cash
         used in operating activities:
         Amortization                                                              2,032         1,232
         Stock compensation expense                                                   50            13
         Inventory provision                                                           -           350
         Deferred income taxes                                                      (207)            -
       Change in operating assets and liabilities:
         Accounts receivable trade                                                (5,470)         (857)
         Income taxes receivable                                                    (124)          612
         Inventory                                                                (2,412)        1,396
         Other current assets                                                     (1,494)        2,208
         Accounts payable                                                           (906)        1,040
         Accrued liabilities                                                      (2,385)       (1,843)
                                                                           ----------------------------
                 Net cash (used in) from operating activities                     (7,386)        9,450
Cash flows from investing activities:
       Additions to capital assets, net                                           (1,520)       (3,993)
       Other, net                                                                 (1,941)       (1,100)
                                                                           ----------------------------
                 Cash used in investing activities                                (3,461)       (5,093)
Cash flows from financing activities:
       Proceeds from issue of common shares, net of
         issue costs                                                               1,403         2,034
       Repayment of bank indebtedness - net                                            -          (483)
       Repayment of loans payable                                                    (90)       (1,034)
                                                                           ----------------------------
                 Net cash from (used in) financing activities                      1,313           517
Effect of currency translation on cash balances                                      (12)           13
                                                                           ----------------------------
(Decrease) increase in cash and cash equivalents                                  (9,546)        4,887
Cash and cash equivalents, beginning of period                                    42,942        38,479
                                                                           ----------------------------
Cash and cash equivalents, end of period                                         $33,396       $43,366
                                                                           ============================
</TABLE>

    See accompanying notes to condensed consolidated financial statements.

                                      -3-
<PAGE>

                        GENESIS MICROCHIP INCORPORATED
             NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                  (unaudited)

1.   Basis of presentation

We have prepared the accompanying unaudited condensed financial statements in
accordance with United States generally accepted accounting principles and
according to the rules and regulations of the Securities and Exchange Commission
for interim financial reporting. Consequently, they do not include all of the
information and footnotes required by United States generally accepted
accounting principles for complete financial statements. These condensed
financial statements should be read in conjunction with our financial statements
and notes thereto for the year ended March 31, 2000 that are included in our
most recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission. We believe that the accompanying financial statements reflect all
adjustments, consisting solely of normal, recurring adjustments, that are
necessary for fair presentation of the results for the interim periods
presented. The results of operations for the period ended September 30, 2000 are
not necessarily indicative of the results to be expected for the full fiscal
year.

2.   Comparative figures

Certain comparative figures have been reclassified to conform with the
presentation in the current period.

3.   Earnings per share

Basic earnings per common share are computed by dividing the net income in a
period by the weighted average number of common shares outstanding during that
period. Diluted earnings per share are calculated in order to give effect to all
potential common shares issuable during the period. The weighted average number
of diluted shares outstanding is calculated by assuming that any proceeds from
potential common shares, such as stock options, are used to repurchase common
shares at the average share price in the period.

Per share information calculated on this basis is as follows (in thousands,
except per share amounts):

<TABLE>
<CAPTION>
                                                                     Three Months Ended             Six Months Ended
                                                                September 30,  September 30,  September 30,  September 30,
                                                                     2000           1999           2000           1999
                                                                ----------------------------- -----------------------------
<S>                                                             <C>            <C>            <C>            <C>
Numerator:
       Net income                                                      $ 1,965       $ 4,026        $ 3,530        $ 5,299
                                                                ============================= =============================

Denominator for basic earnings per share-
       Weighted average common shares outstanding                       19,298        18,499         19,241         18,437
                                                                ============================= =============================

Basic earnings per share                                               $  0.10       $  0.22        $  0.18        $  0.29
                                                                ============================= =============================

Denominator for diluted earnings per share-
       Weighted average common shares outstanding                       19,298        18,499         19,241         18,437
       Stock options and warrants                                          665         1,285            661          1,371
                                                                ----------------------------- -----------------------------
       Shares used in computing diluted earnings per share              19,963        19,784         19,902         19,808
                                                                ============================= =============================

Diluted earnings per share                                             $  0.10       $  0.20        $  0.18        $  0.27
                                                                ============================= =============================
</TABLE>

                                      -4-
<PAGE>

4.   Segmented information

We operate and track our results in one operating segment. We design, develop
and market integrated circuits that manipulate and process digital images.

Revenues from our unaffiliated customers by geographic region were as follows
(in thousands):

<TABLE>
<CAPTION>
                                                    Three Months Ended          Six Months Ended
                                                  September    September     September     September
                                                  30, 2000      30, 1999     30, 2000      30, 1999
                                                -------------------------------------------------------
<S>                                             <C>            <C>           <C>           <C>
United States                                     $     3,342   $    3,988   $     5,190   $     6,937
Japan and Asia                                         10,226       12,080        20,575        25,056
Canada                                                    465          118           712       184,491
Rest of World                                           1,007          176         1,375         4,914
                                                -------------------------------------------------------
                                                  $    15,040   $   16,362   $    27,852   $    32,668
                                                =======================================================
</TABLE>

Net long-lived assets by country of location were as follows (in thousands):

<TABLE>
<CAPTION>
                                                                             September     March 31,
                                                                              30, 2000       2000
                                                                            -------------------------
<S>                                                                         <C>            <C>
United States                                                                 $    4,416   $    3,000
Canada                                                                             7,072        9,000
                                                                            -------------------------
                                                                              $   11,488   $   12,000
                                                                            =========================
</TABLE>

The following table shows the percentage of our revenue in each period that was
derived from customers who individually accounted for more than 10% of revenue
in that period:

<TABLE>
<CAPTION>
                                              Three Months Ended          Six Months Ended
                                         September 30,  September 30,   September 30,  September 30,
                                              2000           2000           2000           1999
                                         -----------------------------------------------------------
<S>                                      <C>            <C>             <C>
Customer A                                          -             13%              -             11%
Customer B                                          -              -              10%             -
</TABLE>

At September 30, 2000 one customer accounted for 11% of accounts receivable
trade. At March 31, 2000, two customers represented 16% and 10% of accounts
receivable trade, respectively.

5.   Recent accounting pronouncements

In June 1998, the Financial Accounting Standards Board issued Statement No. 133,
"Accounting for Derivative Instruments and Hedging Activities," or SFAS 133.
SFAS 133 establishes accounting and reporting standards for derivative
instruments, including certain derivative instruments embedded in other
contracts, and for hedging activities. SFAS 133 requires an entity to recognize
all derivatives as either assets or liabilities in the statement of financial
position and measure those instruments at fair value. The impact of adopting
SFAS 133, which is effective for all fiscal quarters of fiscal years beginning
after June 15, 2000 is not expected to be material to Genesis' operations.

In December 1999, the Securities and Exchange Commission (SEC) issued Staff
Accounting Bulletin No. 101 (SAB 101), Revenue Recognition in Financial
Statements, as amended by SAB 101A, which provides guidance on the recognition,
presentation, and disclosure of revenue in financial statements filed with the
SEC. SAB 101 outlines the basic criteria that must be met to recognize revenue
and provides guidance for disclosures related to revenue recognition policies.
The Company does not expect the adoption of SAB 101 to have a material effect on
its consolidated financial position or results of operations.

                                      -5-
<PAGE>

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains numerous statements of a
forward-looking nature relating to potential future events or to our future
financial performance. Our actual future results may differ significantly from
those forward-looking statements. You should consider the various factors
identified under the caption "Factors that may affect future operating results"
in evaluating those statements.

Overview

We design, develop and market integrated circuits, or chips, that process
digital video and graphic images. Our chips translate source video, graphics and
digital images in order to be able to show them on various display systems such
as flat panel computer monitors or digital televisions. We do not manufacture
our chips. We procure them from third party manufacturers, such as IBM
Corporation, Taiwan Semiconductor Manufacturing Corporation, United
Semiconductor Corporation, and Samsung Semiconductor, Inc.

Applications for our products include:
 .  flat panel computer monitors,
 .  digital CRT computer monitors,
 .  consumer electronics applications, such as digital television and DVD,
 .  digital projection systems, and
 .  advanced image processing applications such as video editing, medical and
    security systems.

Results of operations

The following table shows unaudited statement of operations data for the three
month and six month periods ended September 30, 2000 and September 30, 1999,
expressed as a percentage of revenues:

<TABLE>
<CAPTION>
                                                       Three Months Ended            Six Months Ended
                                                  September 30,  September 30,  September 30,  September 30,
                                                      2000           1999           2000           1999
                                                ------------------------------------------------------------
<S>                                             <C>              <C>            <C>            <C>
Revenues                                                100.0%         100.0%         100.0%          100.0%
Cost of revenues                                         37.2           30.6           35.7            31.4
                                                ------------------------------------------------------------
Gross profit                                             62.8           69.4           64.3            68.6

Operating expenses:
   Research and development                              29.4           22.9           30.4            21.9
   Selling, general and administrative                   23.6           19.0           24.2            19.5
   Merger-related costs                                     -              -              -            10.6
                                                ------------------------------------------------------------
     Total operating expenses                            53.0           41.9           54.6            52.0
                                                ------------------------------------------------------------
Income from operations                                    9.8           27.5            9.7            16.6
Interest income                                           4.9            3.2            4.5             2.8
                                                ------------------------------------------------------------
Income before income taxes                               14.7           30.7           14.2            19.4
Provision for income taxes                                1.6            6.1            1.5             3.2
                                                ------------------------------------------------------------
Net income                                               13.1%          24.6%          12.7%           16.2%
                                                ============================================================
</TABLE>

Revenues: Revenues for the three months ended September 30, 2000 decreased to
$15.0 million from $16.4 million in the three months ended September 30, 1999, a
decrease of 8.1%. This resulted from a decline in average selling prices, offset
in part by an increase in units shipped. The company expects that revenues in
the second half of 2001 and 2002 fiscal years will continue to be dominated by
shipments of product into the flat panel monitor market. As a result of the
timing of the introduction of new products, together with the expected growth of
the flat panel monitor market, the company anticipates sequential quarterly
growth in the December 2000 quarter in the range of 14-16% over the September
quarter and similar sequential growth from the December quarter to the March
2001 quarter. For fiscal 2002 as a whole it is targeting growth of 65 to 75%
over fiscal 2001.

                                      -6-
<PAGE>

Gross Profit. Gross profit for the three months ended September 30, 2000
decreased to $9.4 million from $11.4 million in the three months ended September
30, 1999. As a percentage of revenues, gross profit represented 62.8% of
revenues in the three months ended September 30, 2000, down from 69.4% of
revenues in the three months ended September 30, 1999. The decrease in gross
profit percentage in 2000 over 1999 was primarily attributable to a different
mix of products sold, with the newer products generally having lower average
gross margins, and as a result of our pricing strategy for further increasing
our share of the flat panel computer monitor market. The company expects gross
margins will average in the high 50% range for fiscal 2001, moving toward the
low 50% range in fiscal 2002 as it increases revenues in higher volume markets.

Research and Development. Research and development expenses include costs
associated with research and development personnel, development tools and
prototyping costs. Research and development expenses for the three months ended
September 30, 2000 increased to $4.4 million from $4.0 million in the three
months ended September 30, 1999. These expenses represented 29.4% of revenues in
the 2000 period and 22.9% of revenues in the 1999 period.

The dollar increase in the 2000 period over the comparative period in 1999
reflects higher personnel costs associated with an expansion in our research and
development activities and increased prototype and pre-production expenses for
new products under development. We expect to continue to make substantial
investments in our research and development activities and anticipate that the
dollar amount of research and development expenses will continue to increase.
The increase in research and development expenses as a percentage of revenues is
a result of the decline in revenues from the previous period. This trend is not
intended to continue, as we expect our rate of revenue growth to exceed our rate
of increase in research and development expenses.

Selling, General and Administrative. Selling, general and administrative
expenses consist of personnel and related overhead costs for selling, marketing,
customer support, finance, human resources and general management functions and
of commissions paid to regional sales representatives. Selling, general and
administrative expenses were $3.6 million in the three months ended September
30, 2000 and $3.1 million in the three months ended September 30, 1999. These
expenses represented 23.6% of revenues in the 2000 period and 19.0% of revenues
in the 1999 period.

The dollar increase in 2000 from 1999 in selling, general and administrative
expenses reflects increased personnel costs related to increased administrative,
marketing, selling and customer support personnel and continued expansion of our
international operations. The increase in selling, general and administrative
expenses as a percentage of revenues results from the decline in revenues and
increase in expenses from the previous period. This trend is not intended to
continue, as we expect our rate of revenue growth to exceed our rate of increase
in selling, general and administrative expenses.

Total Operating Expenses. Total operating expenses for the three months ended
September 30, 2000 increased to $8.0 million from $7.1 million in the three
months ended September 30, 1999, for the reasons described above. The company
expects that total operating expenses for the three months ended December 31,
2000 will be relatively unchanged from the three months ended September 30,
2000. For fiscal 2001 it is targeting operating expenses averaging in the
mid-40% range as a percentage of revenue, declining to the mid-30% range in
fiscal 2002.

Interest Income. Interest income in the three months ended September 30, 2000
was $739,000, compared with $515,000 in the three months ended September 30,
1999. Changes in interest income result from changes in the average amount of
cash and cash equivalents on hand, and from interest earned on income taxes and
tax credits recoverable. Future interest income will depend on the amount of
funds available to invest and on future interest rates.

Provision for Income Taxes. We have changed the classification of investment tax
credits (ITC's) in our statement of operations, commencing with the current
fiscal year, to present more clearly the actual spending on research and
development activities. Prior to April 1, 2000, ITC's were classified as a
reduction to research

                                      -7-
<PAGE>

and development expense. ITC's are now shown as a reduction to income tax
expense. The comparative figures for the three months ended September 30, 1999
have been reclassified to conform with the presentation in the current period.
The provisions for income taxes for the three months ended September 30, 2000,
are calculated based on our expected tax rate of approximately 10% for the
entire fiscal year. We have investment tax credits and non-capital losses
available to reduce taxes payable or taxable income. Future income taxes will
depend on our effective tax rates and the distribution of taxable income between
taxation jurisdictions. The company is targeting a longer-term effective income
tax rate of approximately 20%.

Liquidity and capital resources

Cash and cash equivalents were $33.4 million at September 30, 2000. Net cash
used in operations for the six months ended September 30, 2000, was $7.4
million. Prior to changes in operating assets and liabilities, cash of $5.4
million was generated for the six months ended September 30, 2000.

Net cash used in investing activities was $3.5 million in the six months ended
September 30, 2000, due to net capital spending of $1.5 million and an
investment of $2.0 million in Silicon Video Inc., a private company.

Continued expansion of our business may require higher levels of capital
equipment purchases. We have no significant capital spending or purchase
commitments other than purchase commitments made in the ordinary course of
business.

Net cash provided by financing activities in the six months ended September 30,
2000 was $1.3 million. This was primarily a result of funds received for the
purchase of shares under the terms of our stock purchase plan and stock option
plans, offset by our repayment of indebtedness of $0.1 million.

We believe that our existing cash balances together with any cash generated from
our operations will be sufficient to meet our capital requirements on a
short-term basis.

Longer term, we may need to raise additional capital to fund investments in
operating assets to assist in the growth of our business, such as investments in
accounts receivable or inventory, or to purchase capital assets, such as land,
buildings or equipment. Because we do not have our own semiconductor
manufacturing facility, we may be required to make deposits to secure supply in
the future. Although we currently have no plans to raise additional funds, we
could be required or could decide to try and raise additional capital in the
future.

We periodically evaluate acquisitions of businesses, products or technologies
that complement our business. If we were to enter into a transaction of this
nature, we may either have to use a portion of our cash, issue debt or issue
additional equity securities. If we were to issue additional equity securities,
there could be further dilution to our shareholders.

Factors that may affect future operating results

The following factors may have a harmful impact on our business:

Our success will depend on the growth of the flat panel computer monitor market
and other electronics markets

Our ability to generate increased revenues will depend on the growth of the flat
panel computer monitor market. This market is at an early stage of development.
Our continued growth will also depend upon emerging markets for digital CRT
monitors, and for consumer electronics markets, such as home theater, DVD, flat
screen and digital television, and HDTV. The potential size of these markets and
the timing of their development is uncertain and will depend in particular upon:

 .  a significant reduction in the costs of products in the respective markets,
 .  the availability of components required by such products, and
 .  the emergence of competing technologies.

                                      -8-
<PAGE>

For the three months ended September 30, 2000, a substantial portion of our
revenues were derived from sales to customers in the flat panel computer monitor
market. This and other potential markets may not develop as expected, which
would harm our business.

Our products may not be accepted in the flat panel computer monitor market and
other emerging markets

Our success in the flat panel computer monitor market, as well as the markets
for digital CRTs, home theater, DVD, flat panel and digital television, and HDTV
will depend upon the extent to which manufacturers of those products incorporate
our integrated circuits into their products. Our ability to sell products into
these markets will depend upon demand for the functionality provided by our
products. The failure of our products to be accepted in the flat panel computer
monitor market in particular would harm our business.

We must develop new products and enhance our existing products to meet OEM
design requirements and design cycles

We must develop new products and enhance our existing products with improved
technologies to meet rapidly evolving customer requirements and industry
standards. We need to design products for customers that continually require
higher functionality at lower costs. This requires us to continue to add
features to our products and to include all of these features on a single chip.
The development process for these advances is lengthy and will require us to
accurately anticipate technological innovations and market trends. We may be
unable to successfully develop new products or product enhancements. Any new
products or product enhancements may not be accepted in new or existing markets.
If we fail to develop and introduce new products or product enhancements, that
failure will harm our business.

We face intense competition and may not be able to compete effectively

We compete with both large companies and start-up companies, including Macronix
International Co., Ltd., Philips Semiconductors, a division of Philips
Electronics N.V., Pixelworks, Inc., Sage, Inc., Silicon Image, Inc., and ST
Microelectronics, Inc. Our business could be harmed by these existing
competitors announcing or introducing new products. Also, we anticipate that as
the markets for our products develop, our current customers may develop their
own products and competition from diversified electronic and semiconductor
companies will intensify. Some competitors are likely to include companies with
greater financial and other resources than us. This increased competition could
harm our business, by, for example, increasing pressure on our profit margins or
causing us to lose customers.

Our semiconductor products are complex and are difficult to manufacture
cost-effectively.

The manufacture of semiconductors is a complex process. It is often difficult
for semiconductor foundries to achieve acceptable product yields. Product yields
depend on both our product design and the manufacturing process technology
unique to the semiconductor foundry. Since low yields may result from either
design or process difficulties, identifying yield problems can only occur well
into the production cycle, when actual product exists which can be analyzed and
tested.

Defects in our products could increase our costs and delay our product
shipments.

Although we test our products, they are complex and may contain defects and
errors. In the past we have encountered defects and errors in our products.
Delivery of products with defects or reliability, quality or compatibility
problems may damage our reputation and our ability to retain existing customers
and attract new customers. In addition, product defects and errors could result
in additional development costs, diversion of technical resources, delayed
product shipments, increased product returns, and product liability claims
against us which may not be fully covered by insurance. Any of these could harm
our business.

We subcontract our manufacturing, assembly and test operations.

                                      -9-
<PAGE>

We do not have our own fabrication facilities, assembly or testing operations.
Instead, we rely on others to fabricate, assemble and test all of our products.
We have our products manufactured by IBM, United Semiconductor Corporation,
Taiwan Semiconductor Manufacturing Corporation and Samsung Semiconductor, Inc.
No single product is purchased from more than one supplier. There are many risks
associated with our dependence upon outside manufacturing, including:

 .  reduced control over manufacturing and delivery schedules of products,
 .  potential political or environmental risks in the countries where the
   manufacturing facilities are located,
 .  reduced control over quality assurance,
 .  difficulty of management of manufacturing costs and quantities,
 .  potential lack of adequate capacity during periods of excess demand, and
 .  potential unauthorized use of intellectual property.

We depend upon outside manufacturers to fabricate silicon wafers on which our
integrated circuits are imprinted. These wafers must be of acceptable quality
and in sufficient quantity and the manufacturers must deliver them to assembly
and testing subcontractors on time for packaging into final products. We have at
times experienced delivery delays and long manufacturing lead times. These
manufacturers fabricate, test and assemble products for other companies. We
cannot be sure that our manufacturers will devote adequate resources to the
production of our products or deliver sufficient quantities of finished products
to us on time or at an acceptable cost. The lead-time necessary to establish a
strategic relationship with a new manufacturing partner is considerable. We
would be unable to readily obtain an alternative source of supply for any of our
products if this proves necessary. Any occurrence of these manufacturing
difficulties could harm our business.

Our third-party wafer foundries, third-party assembly and test subcontractors
and significant customers are located in an area susceptible to earthquakes.

All of our outside foundries and most of our third party assembly and test
subcontractors are located in Taiwan, which is an area susceptible to
earthquakes. In addition, some of our significant customers are located in
Taiwan. Damage caused by earthquakes in Taiwan may result in shortages in water
or electricity or transportation which could limit the production capacity of
our outside foundries and the ability of subcontractors to provide assembly and
test services. Any reduction in production capacity or the ability to provide
assembly and test services could cause delays or shortages in our product
supply, which would harm our business. Customers located in Taiwan were
responsible for 46.2% of our product revenue for the three months ended
September 30, 2000. If the facilities or equipment of these customers are
damaged by future earthquakes, they could reduce their purchases of our
products, which would harm our business. In addition, the operations of
suppliers to our outside foundries and our Taiwanese customers could be
disrupted by future earthquakes, which could in turn harm our business by
resulting in shortages in our product supply or reduced purchases of our
products.

A large percentage of our revenues come from sales to a small number of large
customers

The markets for our products are highly concentrated. Our sales are derived from
a limited number of customers. Sales to our largest five customers accounted for
34.3% of our revenues for the three months ended September 30, 2000. We expect
that a small number of customers will continue to account for a large amount of
our revenues. All of our sales are made on the basis of purchase orders rather
than long-term agreements so that any customer could cease purchasing products
at any time without penalty. The decision by any large customer to decrease or
cease using our products would harm our business.

                                      -10-
<PAGE>

We do not have long-term commitments from our customers, and we allocate
resources based on our estimates of customer demand.

Our sales are made on the basis of purchase orders rather than long-term
purchase commitments. In addition, our customers may cancel or defer purchase
orders for reasons outside our control, such as supply constraints for other
components incorporated into their products. We manufacture our products
according to our estimates of customer demand. This process requires us to make
multiple demand forecast assumptions, each of which may introduce error into our
estimates. If we overestimate customer demand, we may allocate resources to
manufacturing products which we may not be able to sell. As a result, we would
have excess inventory, which would increase our losses. Conversely, if we
underestimate customer demand or if sufficient manufacturing capacity is
unavailable, we would forego revenue opportunities, lose market share and damage
our customer relationships.

Our lengthy sales cycle can result in uncertainty and delays in generating
revenues.

Because our products are based on new technology and standards, a lengthy sales
process, typically requiring several months or more, is often required before
potential customers begin the technical evaluation of our products. This
technical evaluation can then exceed six months. It can take an additional six
months before a customer commences volume shipments of systems that incorporate
our products. However, even when a manufacturer decides to design our products
into its systems, the manufacturer may never ship systems incorporating our
products. Given our lengthy sales cycle, we experience a delay between the time
we increase expenditures for research and development, sales and marketing
efforts and inventory and the time we generate revenues, if any, from these
expenditures. As a result, our business could be harmed if a significant
customer reduces or delays orders or chooses not to release products
incorporating our products.

Our business depends on relationships with industry leaders that are non-binding

We work closely with industry leaders in the markets we serve to design products
with improved performance, cost and functionality. We typically commit
significant research and development resources to such design activities. We
often divert financial and personnel resources from other development projects
without entering into agreements obligating these industry leaders to continue
the collaborative design project or to purchase the resulting products. The
failure of an industry leader to complete development of a collaborative design
project or to purchase the products resulting from such projects would have an
immediate and serious impact on our business, financial condition and results of
operations. Our inability to establish such relationships in the future would,
similarly, harm our business.

A large percentage of our revenues will come from sales outside of North
America, which creates additional business risks

A large portion of our revenues will come from sales to customers outside of
North America, particularly to equipment manufacturers located in Japan and
other parts of Asia. For the three months ended September 30, 2000, sales to
regions outside of North America amounted to 75% of revenues. These sales are
subject to numerous risks, including:

 .  fluctuations in currency exchange rates, tariffs, import restrictions and
   other trade barriers,
 .  unexpected changes in regulatory requirements,
 .  longer payment periods,
 .  potentially adverse tax consequences,
 .  export license requirements,
 .  political and economic instability, and
 .  unexpected changes in diplomatic and trade relationships.

Because our sales are denominated in United States dollars, increases in the
value of the United States dollar could increase the price of our products in
non-U.S. markets and make our products more expensive than competitors' products
denominated in local currencies.

                                      -11-
<PAGE>

The cyclical nature of the semiconductor industry may lead to significant
variances in the demand for our products.

In the past, the semiconductor industry has been characterized by significant
downturns and wide fluctuations in supply and demand. Also, the industry has
experienced significant fluctuations in anticipation of changes in general
economic conditions, including economic conditions in Asia. This cyclicality has
led to significant variances in product demand and production capacity. It has
also accelerated erosion of average selling prices per unit. We may experience
periodic fluctuations in our future financial results because of changes in
industry-wide conditions.

We may be unable to adequately protect our intellectual property. We rely on a
combination of patent, copyright, trademark and trade secret laws, as well as
nondisclosure agreements and other methods to protect our proprietary
technologies.

We have been issued patents and have a number of pending United States and
foreign patent applications. However, we cannot assure you that any patent will
be issued as a result of any applications or, if issued, that any claims allowed
will be sufficiently broad to protect our technology. In addition, it is
possible that existing or future patents may be challenged, invalidated or
circumvented. It may be possible for a third party to copy or otherwise obtain
and use our products, or technology without authorization, develop similar
technology independently or design around our patents. Effective copyright,
trademark and trade secret protection may be unavailable or limited in foreign
countries.

Others may bring infringement claims against us which could be time-consuming
and expensive to defend.

In recent years, there has been significant litigation in the United States
involving patents and other intellectual property rights. This litigation is
widespread in the high-technology industry and is particularly prevalent in the
semiconductor industry, where a number of companies aggressively use their
patent portfolios by bringing numerous infringement claims. In addition, in
recent years, there has been an increase in the filing of so-called "nuisance
suits" alleging infringement of intellectual property rights, which pressure
defendants into entering settlement arrangements to quickly dispose of such
suits, regardless of their merits. We may become a party to litigation in the
future to protect our intellectual property or as a result of an alleged
infringement of others' intellectual property. These lawsuits could subject us
to significant liability for damages and invalidate our proprietary rights.
These lawsuits, regardless of their success, would likely be time-consuming and
expensive to resolve and would divert management time and attention. Any
potential intellectual property litigation also could force us to do one or more
of the following:

 .  stop selling products or using technology that contain the allegedly
   infringing intellectual property;
 .  attempt to obtain a license to the relevant intellectual property, which
   license may not be available on reasonable terms or at all; and
 .  attempt to redesign those products that contain the allegedly infringing
   intellectual property.

If we are forced to take any of these actions, we may be unable to manufacture
and sell some of our products, which could harm our business.

We are growing rapidly, which strains our management and resources.

We are experiencing a period of significant growth that will continue to place a
great strain on our management and other resources. To manage our growth
effectively, we must:

 .  implement and improve operational and financial systems;
 .  train and manage our employee base; and
 .  attract and retain qualified personnel with relevant experience.

                                      -12-
<PAGE>

We must also manage multiple relationships with customers, business partners,
and other third parties, such as our foundry and test partners. Moreover, we
will spend substantial amounts of time and money in connection with our rapid
growth and may have unexpected costs. Our systems, procedures or controls may
not be adequate to support our operations and we may not be able to expand
quickly enough to exploit potential market opportunities. Our future operating
results will also depend on expanding sales and marketing, research and
development and administrative support. If we cannot attract qualified people or
manage growth effectively, our business would be seriously harmed.

We may not be able to attract or retain the key personnel we need to succeed

Competition for qualified management, engineering and technical employees is
intense. As a result, employees could leave with little or no prior notice. We
cannot assure you that we will be able to attract and retain employees.

If we cannot attract and retain key employees, our business would be harmed.

We may make future acquisitions where advisable and acquisitions involve
numerous risks

Our growth is dependent upon market growth and our ability to enhance our
existing products and introduce new products on a timely basis. One of the ways
we may address this need to develop new products is through acquisitions of
other companies. Acquisitions involve numerous risks, including the following:

 .  We may experience difficulty in assimilating the acquired operations and
   employees;
 .  We may be unable to retain the key employees of the acquired
   operation;
 .  The acquisition may disrupt our ongoing business;
 .  We may not be able to incorporate successfully the acquired technology and
   operations into our business and maintain uniform standards, controls,
   policies and procedures; and
 .  We may lack the experience to enter into new markets, products or
   technologies.

Acquisitions of high-technology companies are inherently risky, and no assurance
can be given that our future acquisitions, if any, will be successful and will
not adversely affect our business, operating results or financial condition. We
must also maintain our ability to manage any such growth effectively. Failure to
manage growth effectively and successfully integrate acquisitions made by us
could materially harm our business and operating results.

Other factors to consider

You should also consider the following factors:

It may be difficult for our shareholders to enforce civil liabilities under the
United States federal securities laws because we are incorporated in Canada

The enforcement by our shareholders of civil liabilities under the federal
securities laws of the United States may be adversely affected because:

 .  we are incorporated under the laws of Nova Scotia, Canada,
 .  some of our directors and officers are residents of Canada, and
 .  substantial portions of our assets are located outside the United States.

As a result, it may be difficult for holders of our common shares to effect
service of a legal claim within the United States upon our directors and
officers or upon other individuals who are not residents of the United States.
It may also be difficult to satisfy any judgements of courts of the United
States based upon civil liabilities under the federal securities laws of the
United States.

                                      -13-
<PAGE>

Our anti-takeover defense provisions may deter potential acquirers

Our authorized capital consists of 1,000,000,000 special shares issuable in one
or more series and 1,000,000,000 common shares. Our board of directors has the
authority to issue special shares and to determine the price, designation,
rights, preferences, privileges, restrictions and conditions of these shares
without any further vote or action by our shareholders, including voting and
dividend rights. The rights of holders of our common shares will be subject to,
and may be adversely affected by, rights of holders of any special shares that
we may issue in the future. The issuance of special shares could make it more
difficult for a third party to acquire a majority of our outstanding voting
shares. We have no present plans to issue any special shares. We have adopted a
shareholder rights plan with respect to our common shares. This plan is
specifically designed to make an unsolicited, non-negotiated takeover attempt
more difficult. We also have a board of directors with three-year staggered
terms, which may, in certain circumstances, make an unsolicited, non-negotiated
takeover attempt more difficult.

ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We carry out a significant portion of our operations in Canada. Although
virtually all our revenues and costs of revenues are denominated in U.S.
dollars, a substantial portion of our operating expenses are denominated in
Canadian dollars. Accordingly, our operating results are affected by changes in
the exchange rate between the Canadian and U.S. dollars. Any future
strengthening of the Canadian dollar against the US dollar could negatively
impact our operating results by increasing our operating expenses. We do not
presently engage in any hedging or other transactions intended to manage the
risks relating to foreign currency exchange rate fluctuations, other than
natural hedges that occur as a result of holding both Canadian dollar
denominated assets and Canadian dollar denominated liabilities. We may in the
future undertake hedging or other such transactions if management determines
that it is necessary to offset exchange rate risks. To date, net exchange gains
and losses on Canadian dollar denominated assets and liabilities has not been
material.

PART II:  OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of September 30, 2000, we were not a party to any material legal proceedings.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At our Annual and Special General Meeting of Shareholders held on September 14,
2000, the following proposals were considered by shareholders:

1. A resolution electing four directors, as described in the information
circular accompanying the proxy.

2. A resolution appointing KPMG LLP as auditors for the year ending March 31,
2001.

3. A special resolution giving Genesis the authority to acquire its own shares,
as described in the information circular accompanying the proxy.

4. A special resolution giving the Board of Directors the authority to exercise
the powers under subsection 26(4) of the Companies Act (Nova Scotia) described
in the information circular accompanying the proxy.

5. A special resolution approving the amendments to the articles of association
as described in the information circular accompanying the proxy.

6. A resolution approving the amendments to the 1997 Non-Employee Stock Option
Plan as described in the information circular accompanying the proxy.

7. A resolution approving the amendments to the 2000 Non-Statutory Stock Option
Plan as described in the information circular accompanying the proxy.

                                      -14-
<PAGE>

8. A resolution approving the amendments to the 1997 Employee Stock Purchase
Plan as described in the information circular accompanying the proxy.

The following table shows the results of the vote on proposals 3, 4 and 5, the
special resolutions, at the meeting:

   Proposal
    Number       For          Against        Withheld or
                                              Abstained
---------------------------------------------------------
         3      8,264,031        166,648       10,900,737
         4      8,024,972        405,707       10,900,737
         5      4,705,485      3,725,194       10,900,076

Because these were special resolutions, they required at least 75% of the votes
present at the meeting to approve them in order to be passed. An abstention or
non-vote effectively counted as a vote against a proposal. Consequently,
proposals 3, 4 and 5 did not pass.

The following table shows the results of the voting on the remaining proposals:

   Proposal
    Number       For          Against        Withheld or
                                              Abstained
---------------------------------------------------------
         1     15,247,843              -          139,386
         2     15,300,848         86,381        3,944,187
         6      6,041,603      2,389,076       10,900,737
         7      5,958,495      2,472,184       10,900,737
         8      6,284,664      2,086,015       10,900,737

Because these were not special resolutions, a simple majority of votes cast were
required to pass these proposals and abstentions or non-votes did not count
either for or against the proposal. Consequently proposals 1, 2, 6, 7 and 8 were
passed at the meeting and became immediately effective.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a)   The following exhibits are attached:

       10.1  License Agreement, dated as of July 21, 2000, between Silicon Video
             Inc. and Genesis Microchip Inc.
       27.1  Financial Data Schedule

b)   Reports on Form 8-K:

       We filed no reports on Form 8-K in the three months ended September 30,
2000.

SIGNATURE

Our authorized representative has signed this report on our behalf as required
by the Securities Exchange Act of 1934.

                                   GENESIS MICROCHIP INCORPORATED

                                   By:  /s/ I. ERIC ERDMAN
                                      ---------------------------------
                                      I. Eric Erdman
                                      Chief Financial Officer & Secretary
                                      (Authorized Officer &
                                      Principal Financial Officer)

Date: November 14, 2000

                                      -15-


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission